Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of nilotinib in monozygotic twins with spinocerebellar ataxia type 6

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Choi JY, Glasauer S, Kim JH, Zee DS, Kim JS (2018) Characteristics and mechanism of apogeotropic central positional nystagmus. Brain 141:762–775

    Article  PubMed  Google Scholar 

  2. Gomez CM, Thompson RM, Gammack JT, Perlman SL, Dobyns WB, Truwit CL, Zee DS, Clark HB, Anderson JH (1997) Spinocerebellar ataxia type 6: gaze-evoked and vertical nystagmus, Purkinje cell degeneration, and variable age of onset. Ann neurol 42:933–950

    Article  CAS  PubMed  Google Scholar 

  3. Hebron ML, Lonskaya I, Moussa CEH (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of -synuclein in Parkinsons disease models. Hum Mol Genet 22:3315–3328

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P, Durr A, Marelli C, Globas C, Linnemann C, Schols L, Rakowicz M, Rola R, Zdzienicka E, Schmitz-Hubsch T, Fancellu R, Mariotti C, Tomasello C, Baliko L, Melegh B, Filla A, Rinaldi C, van de Warrenburg BP, Verstappen CC, Szymanski S, Berciano J, Infante J, Timmann D, Boesch S, Hering S, Depondt C, Pandolfo M, Kang JS, Ratzka S, Schulz J, Tezenas du Montcel S, Klockgether T (2011) The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology 77:1035–1041

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Klockgether T, Mariotti C, Paulson HL (2019) Spinocerebellar ataxia. Nat Rev Dis Primers 5:24

    Article  PubMed  Google Scholar 

  6. Lee WJ, Moon J, Kim TJ, Jun JS, Lee HS, Ryu YJ, Lee ST, Jung KH, Park KI, Jung KY, Kim M, Lee SK, Chu K (2017) The c-Abl inhibitor, nilotinib, as a potential therapeutic agent for chronic cerebellar ataxia. J Neuroimmunol 309:82–87

    Article  CAS  PubMed  Google Scholar 

  7. Lindholm D, Pham DD, Cascone A, Eriksson O, Wennerberg K, Saarma M (2016) c-Abl inhibitors enable insights into the pathophysiology and neuroprotection in Parkinson’s disease. Front Aging Neurosci 8:254

    Article  PubMed  PubMed Central  Google Scholar 

  8. Pagan F, Hebron M, Valadez EH, Torres-Yaghi Y, Huang X, Mills RR, Wilmarth BM, Howard H, Dunn C, Carlson A, Lawler A, Rogers SL, Falconer RA, Ahn J, Li Z, Moussa C (2016) Nilotinib effects in parkinson’s disease and dementia with lewy bodies. J Parkinsons Dis 6:503–517

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, Investigators EN (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251–2259

    Article  CAS  PubMed  Google Scholar 

  10. Schlatterer SD, Acker CM, Davies P (2011) c-Abl in neurodegenerative disease. J Mol Neurosci 45:445–452

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Sullivan R, Yau WY, O’Connor E, Houlden H (2019) Spinocerebellar ataxia: an update. J Neurol 266:533–544

    Article  PubMed  Google Scholar 

  12. Turner RS, Hebron ML, Lawler A, Mundel EE, Yusuf N, Starr JN, Anjum M, Pagan F, Torres-Yaghi Y, Shi W, Mulki S, Ferrante D, Matar S, Liu X, Esposito G, Berkowitz F, Jiang X, Ahn J, Moussa C (2020) Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer’s disease. Ann Neurol 88:183–194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wang X, Wang H, Xia Y, Jiang H, Shen L, Wang S, Shen R, Xu Q, Luo X, Tang B (2010) Spinocerebellar ataxia type 6: Systematic patho-anatomical study reveals different phylogenetically defined regions of the cerebellum and neural pathways undergo different evolutions of the degenerative process. Neuropathology 30:501–514

    CAS  PubMed  Google Scholar 

  14. Zhou Y, Yamamura Y, Ogawa M, Tsuji R, Tsuchiya K, Kasahara J, Goto S (2018) c-Abl inhibition exerts symptomatic antiparkinsonian effects through a striatal postsynaptic mechanism. Front Pharmacol 9:1311

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

None.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Biomedical Research Institute, Busan, South Korea

    Seo-Young Choi & Kwang-Dong Choi

  2. Research Administration Team, Seoul National University Bundang Hospital, Seongnam, South Korea

    Hyo-Jung Kim

  3. Department of Neurology, College of Medicine, Dizziness Center, Seoul National University Bundang Hospital, Seoul National University, 173-82 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, South Korea

    Ji-Soo Kim

  4. Department of Neurology, Seoul National University College of Medicine, Seoul, South Korea

    Ji-Soo Kim

Authors
  1. Seo-Young Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hyo-Jung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kwang-Dong Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ji-Soo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Dr. S.Y. Choi conducted the experiments, analyzed and interpreted the data, and wrote the manuscript. Drs. K.D. Choi and H.J. Kim analyzed and interpreted the data.

Prof. J.S. Kim conducted the design and conceptualization of the study, interpretation of the data, and revised the manuscript.

Corresponding author

Correspondence to Ji-Soo Kim.

Ethics declarations

Conflicts of interest

Drs. S.Y. Choi, K.D. Choi, and H.J. Kim report no disclosure. Prof. J.S. Kim serves as an associate editor of Frontiers in Neuro-otology and on the editorial boards of the Journal of Clinical Neurology, Frontiers in Neuro-ophthalmology, Journal of Neuro-ophthalmology, Journal of Vestibular Research, Journal of Neurology, Medicine, and Clinical and Translational Neuroscience.

Ethical standard

This study followed the tenets of the Declaration of Helsinki, and was performed according to the guidelines of Institutional Review Board of Pusan National University Hospital (1907–006-080). Signed patient consent-to-disclose forms were also obtained.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Choi, SY., Kim, HJ., Choi, KD. et al. Efficacy of nilotinib in monozygotic twins with spinocerebellar ataxia type 6. J Neurol 269, 2769–2773 (2022). https://doi.org/10.1007/s00415-021-10895-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-021-10895-x

Search

Navigation